But the evidence base underpinning that optimistic narrative is now under formal challenge. In a Matters Arising letter published in the same journal, a team of researchers led by Khayrullina Aliya Khakimovna of Tashkent State Medical University, together with Samadov Bakhodirjon and J. Joseph Armstrong, has identified three distinct areas of concern in the review, ranging from technical citation errors to what they describe as a substantive asymmetry in how clinical evidence was presented. Their critique is not a rejection of nanomedicine itself; rather, it is a call for the kind of bibliographic rigor and evidentiary balance that readers need when weighing whether a field truly stands on the verge of clinical impact.

The first and most visible problem concerns the review’s reference list, which contains 211 numbered entries. According to the letter, several sources appear more than once under separate numbers with identical content. References 6 and 8 both point to the same landmark 2015 Nature paper by Waddell and colleagues that redefined the mutational landscape of pancreatic cancer through whole-genome sequencing. References 9 and 21 duplicate the same Hu review of pancreatic cancer epidemiology. The pattern continues with references 55 and 89, which both cite an identical targeted drug delivery review by Yu; references 106 and 117, which duplicate the same Ahmad study of a DHA-SBT-1214 formulation; and references 132 and 143, which repeat the same Pontón and Sánchez-García review of nanocarriers for combination therapy in pancreatic ductal adenocarcinoma.

The letter’s authors argue that this recurring pattern is more consequential than an isolated typographical slip. Duplicate citations of this kind are precisely the sort of error that modern reference-management software and a careful pre-submission verification pass are designed to catch. When the same source is cited under different numbers scattered across a bibliography, the authors contend, it raises a broader question about how carefully the remaining two hundred-plus citations were checked against the claims they are meant to support. A reader cannot independently confirm that each attribution is accurate without tracing every source individually, which transforms the reference list from a reliable scholarly apparatus into something closer to an unverified inventory.

The second issue involves a curious artifact in the review’s Table 6, which summarizes clinical trials of nanocarrier platforms. The table lists the NanoSMART trial and the NBTXR3 trial with citation markers written as NCT04789486 followed by the bracketed number 639, and NCT04484909 followed by 640. The problem is arithmetical: the reference list contains only 211 entries, so bracketed numbers 639 and 640 correspond to nothing in the bibliography as submitted. The letter suggests these markers are residual remnants carried over from a source document organized under a different, larger numbering scheme—one that was never fully reconciled with the manuscript’s own citation system during compilation.

On its own, this particular error is unlikely to mislead anyone about the trials themselves, since the correct clinical trial registry identifiers from ClinicalTrials.gov are also provided, allowing readers to locate the studies directly. But the letter frames it as a visible marker of the same compilation carelessness evident in the duplicated citations elsewhere, and as belonging to the class of errors that peer review and editorial proofing exist specifically to intercept before a manuscript reaches the literature. In an era when bibliometric indicators and citation counts feed into assessments of scientific influence, corrupted citation networks propagate quietly through subsequent papers that inherit the errors.

The third and substantively weightiest concern involves what the review left out rather than what it got wrong. Table 6 lists NC-6004, a micellar formulation of the chemotherapy drug cisplatin, as having reached a completed phase III trial in combination with gemcitabine, the standard backbone of pancreatic cancer chemotherapy. The trial in question, registered as NCT02043288, is the only completed phase III study listed in the review’s entire evidence table. Yet, according to the letter, the review reports only the trial’s phase and status, not its outcome. For a paper whose central argument is that lipid- and micelle-based nanocarriers represent a translationally viable strategy for pancreatic cancer, the silence is striking: the single late-stage clinical test cited in the evidence table has a result, and the reader is not told what it is.

The omission matters, the letter argues, because of how the surrounding text frames the field’s trajectory. Sections 7 and 8 of the review place considerable weight on translational promise and devote extended discussion to nab-paclitaxel—an albumin-bound paclitaxel formulation approved for pancreatic cancer—as a precedent for the successful clinical translation of lipid- and protein-based carriers. That single positive case is treated as representative of the field’s direction of travel. A symmetric account, the letter’s authors contend, would also plainly state what happened when a comparable platform, NC-6004, reached the same late stage of testing. A reader attempting to judge whether nanocarrier strategies for pancreatic cancer are broadly promising or narrowly successful in one or two specific formulations needs both outcomes, favorable or not, to form that judgment.

The letter is careful to note that reporting a negative or non-superior result alongside the positive precedent would not undermine the review’s broader mechanistic case. Nanocarrier biology—the enhanced permeability of tumor vasculature, the potential for ligand-directed targeting, the pharmacokinetic advantages of encapsulated cytotoxics—remains scientifically grounded regardless of how any single trial turned out. But omitting the one completed phase III result while extensively documenting regulatory and patent precedent for approval, the authors write, creates an asymmetry between how thoroughly favorable and unfavorable evidence is documented. They point to a growing literature on scientific integrity and publication practices suggesting that such selective framing, even when unintentional, distorts the evidentiary record on which clinicians and researchers rely.

Importantly, the critique is not a dismissal. The letter explicitly credits the original review with compiling an extensive and genuinely useful catalogue of lipid-based nanocarrier platforms, targeting strategies, and regulatory precedents relevant to pancreatic ductal adenocarcinoma, noting that the patent and regulatory sections in particular gather information not easily found consolidated elsewhere. The requested remedies are equally specific: correct the duplicated references and reconcile the full bibliography against every in-text citation, resolve the stray reference numbers in Table 6, and report the completed phase III outcome for NC-6004 so that the review’s central claim about nanocarrier translatability can be weighed against the complete record of late-stage clinical testing rather than against successful precedents alone. Whether the journal and the original authors respond with a formal correction, and what the NC-6004 result ultimately shows, will determine how much weight the field’s nanomedicine literature can bear.

Subject of Research: Editorial integrity concerns in a review of theranostic lipid nanocarriers for pancreatic ductal adenocarcinoma

Article Title: Comment on “Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma”

Article References: Khakimovna, K. A., Bakhodirjon, S., & Armstrong, J. J. (2026). Comment on “Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma”. Journal of Cancer Research and Clinical Oncology, 152(9), Article 187. https://doi.org/10.1007/s00432-026-06618-2

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06618-2

Keywords: theranostics, lipid nanocarriers, pancreatic ductal adenocarcinoma, nanomedicine, drug delivery, phase III trial, NC-6004, citation errors, scientific integrity, matters arising, precision oncology, clinical translation